spacer
home > ebr > winter 2001 > recent progress in tumour immunology and prospects for therapeutic intervention
PUBLICATIONS
European Biopharmaceutical Review

Recent Progress in Tumour Immunology and Prospects for Therapeutic Intervention

The concept that human tumours evoke immune responses in patients which might be harnessed for therapeutic benefit is at least a century old. Numerous, uncontrolled active immunisation studies with autologous or allogeneic tumour preparations have been undertaken, which frequently revealed anecdotal responses but failed to translate into significant results in large, randomised studies. To date, only two products, Melacine (an allogeneic cell vaccine incorporating an immunologic adjuvant for malignant melanoma) and M-Vax (an autologous melanoma cell vaccine) have gained regulatory approval, in single territories.Understanding of the molecular basis of human tumour antigen recognition has been greatly enhanced in recent years, through application of the tools of molecular genetics. These advances have helped to redefine the challenges involved in cancer immunotherapy and to provide the basis for a more empirical approach than has hitherto been achievable.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Michael Moore, Chief Scientific Officer and Research Director at Xenova

Michael Moore received his PhD at the University of Nottingham and subsequently established the Immunology Group at the Paterson Institute for Cancer Research, Manchester, UK. He obtained both his DSc and his Fellowship of the Royal College of Pathologists in 1986. Michael joined Xenova in 1988 and held a number of senior executive positions before combining the role of Chief Scientific Officer with Research Director following Xenova's recent merger with Cantab Pharmaceuticals. He is also Visiting Professor in Biology and Biochemistry at Brunel University.
spacer
Dr Michael Moore
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

COPA-DATA USA Announces Office Move to Accommodate Accelerated Growth

COPA-DATA's New Facility in New Jersey Reinforces Innovative Culture and Commitment to Providing Industry-Leading Technology COPA-DATA USA, “We are excited to relocate to our new, larger office in New Jersey,” commented Ray Giffen, Managing Director COPA-DATA USA. “This move represents another significant milestone for our company. The new office space better accommodates our growing team and enables us to hire additional talent that will allow us to continue providing industry-leading support and service.”
More info >>

White Papers

Optimize your Biologic’s Analytical Program for Greater Risk Reduction

Merck

Analytical methods are used throughout upstream and downstream processes to help ensure the desired molecule is being produced with the desired purity. In addition to having the right molecule, quality must be confirmed in terms of glycosylation, oxidation, aggregates, activity and concentration. The analytical package must also ensure that all impurities from the manufacturing process and environment are consistently removed.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement